National Summit Drives Breakthroughs in Veteran and First Responder Wellness
'These communities have sacrificed for our safety and freedom. We owe them systems that work, and work together,' said Eric Golnick, Chairman of NAVFRW and U.S. Navy veteran.
Share
Senior officials from the U.S. Department of Veterans Affairs, Department of Homeland Security, federal law enforcement agencies, state and local first responder organizations, and healthcare leaders participated. Their goal was clear: to share strategies, align systems, and build effective solutions that support those who serve.
'These communities have sacrificed for our safety and freedom. We owe them systems that work, and work together,' said Eric Golnick, Chairman of NAVFRW and U.S. Navy veteran. 'The Summit was a catalyst for that collaboration. The conversations in this room will save lives.'
Panels and working sessions addressed suicide prevention, trauma-informed care, cross-agency partnerships, and gaps between federal systems and community-based services. Many attendees noted this was the first time senior VA officials, public safety leaders, and private-sector wellness innovators had gathered in one place to build a shared path forward.
NAVFRW extends gratitude to the sponsors who made the event possible: Huron Consulting Group, Acadia Healthcare, Optum Serve, ModifyHealth, Thriveworks, and GovContractPros. We also thank our official partner, PsychArmor, for its commitment to education and support for military and first responder communities.
NAVFRW also extends special thanks to Nestlé USA for hosting the event at their headquarters, providing a space where progress could take root.
The NAVFRW Summit marks the beginning of a coordinated national effort to strengthen care systems and save lives through collaboration, evidence-based strategies, and a shared commitment to those who serve.
For more information or to get involved, visit www.navfrw.org.
About NAVFRW
The National Association for Veteran and First Responder Wellness (NAVFRW) is a nonprofit coalition dedicated to improving the health, resilience, and reintegration of veterans and first responders. Through research, convenings, and strategic partnerships, NAVFRW drives systemic change to support those who serve before, during, and after the uniform.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 days ago
- Business Wire
National Summit Drives Breakthroughs in Veteran and First Responder Wellness
WASHINGTON--(BUSINESS WIRE)--On June 3, 2025, the National Association for Veteran and First Responder Wellness (NAVFRW), in partnership with Arlington County Police Department, hosted its inaugural Veteran and First Responder Wellness Summit in Washington, D.C. The event brought together national leaders to strengthen coordination and action around the wellness of veterans and first responders. 'These communities have sacrificed for our safety and freedom. We owe them systems that work, and work together,' said Eric Golnick, Chairman of NAVFRW and U.S. Navy veteran. Share Senior officials from the U.S. Department of Veterans Affairs, Department of Homeland Security, federal law enforcement agencies, state and local first responder organizations, and healthcare leaders participated. Their goal was clear: to share strategies, align systems, and build effective solutions that support those who serve. 'These communities have sacrificed for our safety and freedom. We owe them systems that work, and work together,' said Eric Golnick, Chairman of NAVFRW and U.S. Navy veteran. 'The Summit was a catalyst for that collaboration. The conversations in this room will save lives.' Panels and working sessions addressed suicide prevention, trauma-informed care, cross-agency partnerships, and gaps between federal systems and community-based services. Many attendees noted this was the first time senior VA officials, public safety leaders, and private-sector wellness innovators had gathered in one place to build a shared path forward. NAVFRW extends gratitude to the sponsors who made the event possible: Huron Consulting Group, Acadia Healthcare, Optum Serve, ModifyHealth, Thriveworks, and GovContractPros. We also thank our official partner, PsychArmor, for its commitment to education and support for military and first responder communities. NAVFRW also extends special thanks to Nestlé USA for hosting the event at their headquarters, providing a space where progress could take root. The NAVFRW Summit marks the beginning of a coordinated national effort to strengthen care systems and save lives through collaboration, evidence-based strategies, and a shared commitment to those who serve. For more information or to get involved, visit About NAVFRW The National Association for Veteran and First Responder Wellness (NAVFRW) is a nonprofit coalition dedicated to improving the health, resilience, and reintegration of veterans and first responders. Through research, convenings, and strategic partnerships, NAVFRW drives systemic change to support those who serve before, during, and after the uniform.
Yahoo
24-07-2025
- Yahoo
Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit
MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs) RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces it was selected as the winner of the 2025 Innovation Showcase at the Advanced Wound Care (AWC) Summit held last week in Boston. The award recognizes the most promising early-stage disruptive technology in wound care. During the showcase, Merakris CEO Chris Broderick presented MTX-001, a first-in-class injectable biologic drug therapy derived from purified amniotic fluid for the treatment of non-healing venous leg ulcers (VLUs) including: Total Addressable Market (TAM)/market opportunity & payer strategy Key findings from ongoing Phase 2 clinical trial of investigational new drug MTX-001 Mechanisms of action Production scale manufacturing plan A panel of industry experts selected Merakris for the award based on several criteria including clinical innovation, therapeutic potential, commercialization strategy, and overall impact on the wound care landscape. 'Standard therapies continue to fail many patients suffering from non-healing VLUs,' said Broderick. 'Merakris is pioneering MTX-001 and developing a new class of regenerative biologics that address chronic wound closure. We're honored to be recognized by the AWC Summit for our work to advance care in this underserved patient population.' For strategic partnership and collaboration opportunities, please visit For more information about the MTX-001 clinical trial or Merakris' Expanded Access Program, please contact medaffairs@ About Merakris Therapeutics Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies. Merakris Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris' products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Merakris' management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA. CONTACT: Contact Michelle Murray michelle@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
24-07-2025
- Hamilton Spectator
Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit
RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) — Merakris Therapeutics announces it was selected as the winner of the 2025 Innovation Showcase at the Advanced Wound Care (AWC) Summit held last week in Boston. The award recognizes the most promising early-stage disruptive technology in wound care. During the showcase, Merakris CEO Chris Broderick presented MTX-001, a first-in-class injectable biologic drug therapy derived from purified amniotic fluid for the treatment of non-healing venous leg ulcers (VLUs) including: A panel of industry experts selected Merakris for the award based on several criteria including clinical innovation, therapeutic potential, commercialization strategy, and overall impact on the wound care landscape. 'Standard therapies continue to fail many patients suffering from non-healing VLUs,' said Broderick. 'Merakris is pioneering MTX-001 and developing a new class of regenerative biologics that address chronic wound closure. We're honored to be recognized by the AWC Summit for our work to advance care in this underserved patient population.' For strategic partnership and collaboration opportunities, please visit . For more information about the MTX-001 clinical trial or Merakris' Expanded Access Program, please contact medaffairs@ . About Merakris Therapeutics Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies. Merakris Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris' products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Merakris' management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA.
